[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-neoplasms-malignant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-neoplasms-malignant":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,70,100,129,159,184,212,233,260,284,315,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":44,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100542405","early-detection-of-advanced-adenomas-and-colorectal-cancer-100542405",false,"NCT06342440","Early Detection of Advanced Adenomas and Colorectal Cancer","A Liquid Biopsy Assay For The Non-Invasive Early Detection of Advanced Adenomas and Colorectal Cancer","AACRC","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment.\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer syndromes (identified through genetic testing).\n* Inflammatory bowel diseases.\n* Lack of written informed consent.",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Colorectal Cancer","Colorectal Neoplasms","Colorectal Polyp","Colorectal Adenocarcinoma","Colorectal Disorders","Colorectal Dysplasia","Colorectal Cancer Stage I","Colorectal Cancer Stage II","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Colorectal Neoplasms Malignant","Colorectal Serrated Adenocarcinoma","Colorectal Adenoma With Severe Dysplasia","Colorectal Adenoma With Mild Dysplasia","Colorectal Adenoma With Moderate Dysplasia","Colorectal Adenoma and Carcinoma 1","Colorectal Adenomatous Polyp","Colorectal Adenocarcinoma Metastatic in the Liver",[45,46,47,48,49,50,51,52,53,54,55,56],"Early detection","Micro RNA","miRNA","Liquid biopsy","Machine learning","Artificial Intelligence","Incidence","Polypectomy","Screening","Surveillance","Exosome","Vascicles","RECRUITING","2026-06-15",{"date":60,"type":61},"2026-06-17","ACTUAL",{"date":63,"type":61},"2020-03-15",{"date":65,"type":22},"2026-06-18",{"name":67,"class":68},"City of Hope Medical Center","OTHER",6,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100575907","phase-2-delayed-systemic-therapy-following-destructive-local-treatment-of-pulmonary-oligometastases-after-no-evidence-of-disease-ned-in-colorectal-cancer-100575907","NCT06778382","Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.","Deferred Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After NED in Colorectal Cancer： A Phase II, Single-Arm Clinical Trail.","Inclusion Criteria:\n\n* Patients with a pathologically confirmed diagnosis of colorectal cancer with the following disease conditions:\n\n  1. The patient has achieved No Evidence of Disease (NED) after undergoing EMR, surgery, radiofrequency ablation, or radiotherapy.\n  2. NED has been maintained for ≥ 6 months.\n  3. The patient has not received chemotherapy, or has only received postoperative adjuvant chemotherapy or first-line systemic therapy.\n  4. Oligometastatic lung lesions (defined as 5 or fewer lesions) detected after ≥ 6 months of NED maintenance, eligible for destructive therapy.\n  5. No prior radiotherapy to the lungs.\n* RECIST 1.1 criteria: The patient must have measurable lesions, defined as at least one nodal lesion with a longest diameter \\> 1.5 cm, or at least one nodal lesion \\> 1 cm with an accurately measurable pendulous diameter.\n* ECOG performance status: ≤ 2 (Eastern Cooperative Oncology Group general condition score).\n* The patient's expected survival must be ≥ 3 months.\n* Adequate hematologic function: Absolute neutrophil count ≥ 1.6 x 10⁹\u002FL, with no growth factor support for at least 7 days prior to testing.\n* Normal organ function: The patient must be able to tolerate at least one of the local destructive treatments, as assessed by the corresponding department's physician, based on normal hepatic, renal, pulmonary, and cardiac function.\n* Reproductive age: Female patients of childbearing potential must agree to use a reliable method of contraception with their partner from the time of informed consent until 1 year after treatment completion.\n* The patient must have voluntarily provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n* First diagnosis of advanced colorectal cancer with metastatic disease.\n* Multiple lung metastases (\\> 5 lesions), liver metastasis, bone metastasis, or lymph node metastasis.\n* Lung metastases that are not amenable to radiotherapy, as determined by the investigator.\n* Previously received second-line or higher systemic treatment.\n* Liver or kidney dysfunction: Alanine aminotransferase (ALT) \\> 3 times the upper limit of normal; Aspartate aminotransferase (AST) \\> 3 times the upper limit of normal; Total bilirubin (TBIL) \\> 2 times the upper limit of normal; Serum creatinine \\> 1.5 times the upper limit of normal.\n* Elevated tumor marker: CEA ≥ 50 ng\u002FmL.\n* Serious medical conditions that may interfere with the study (e.g., uncontrolled diabetes, gastric ulcers, severe cardiopulmonary diseases), at the discretion of the researchers.\n* Severe or uncontrolled infections.\n* Active autoimmune disease.\n* Clinically significant central nervous system dysfunction.\n* Recent major surgery (excluding lymph node biopsy) within the last 30 days.\n* Pregnant or breastfeeding women of childbearing age who are not using contraception.\n* Drug allergy to study treatments.\n* Other reasons, as determined by the researchers, that make the patient unsuitable for participation.","75 Years",{"count":79,"type":22},22,"INTERVENTIONAL",[82],"PHASE2","Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the medical community and patients. Postoperative chemotherapy, as an important adjuvant therapy, is widely used in CRC patients aiming to reduce the risk of recurrence. Despite extensive research on the efficacy of postoperative chemotherapy in CRC, the mechanisms of postoperative recurrence, predictive factors, and strategies to enhance chemotherapy effectiveness remain unclear. For colorectal cancer patients who have achieved NED (No Evidence of Disease), the decision to either reinitiate or change the systemic chemotherapy regimen for newly developed pulmonary oligometastases remains controversial. Local treatment options for diagnosing oligometastases include surgery, radiotherapy, and radiofrequency ablation. However, whether systemic treatment should be added after local treatment in patients who have achieved NED remains uncertain , and this issue requires urgent resolution.",[36],[36,86,87,88,89],"No evidence of disease","Lung metastases","Oligometastasis","Time without systemic therapy","2026-04-27",{"date":92,"type":61},"2026-04-28",{"date":94,"type":61},"2024-06-24",{"date":96,"type":22},"2026-11-01",{"name":98,"class":68},"Shandong Cancer Hospital and Institute",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":128},"100542402","early-onset-colorectal-cancer-detection-100542402","NCT06342401","Early Onset Colorectal Cancer Detection","Development and Validation fo an Exosome-Based and Machine Learning Powered Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer","ENCODE","Inclusion Criteria:\n\n* Stage I, II, III, IV colorectal cancer (TNM classification, 8th edition) diagnosed before the age of 50 (EOCRC cases)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment\n* Colonoscopy-proven cancer-free status at the time of study inclusion (Non-disease controls)\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer syndromes (identified through genetic testing)\n* Inflammatory bowel diseases\n* Lack of written informed consent","50 Years",{"count":110,"type":22},400,"Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women.\n\nThis study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid)",[26,27,29,32,35,33,34,36],[114,115,116,117,118,119,120,48],"Early onset","Young onset","Young adult","micro-RNA","Rectal cancer","Cancer of the young","Cancer detection","2026-01-27",{"date":123,"type":61},"2026-01-28",{"date":125,"type":61},"2023-04-15",{"date":65,"type":22},{"name":67,"class":68},13,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":80,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100592160","smart-measurement-of-circulating-tumor-dna-100592160","NCT06989814","Smart Measurement of Circulating Tumor DNA","Smart Measurement of Circulating Tumor DNA: a Tumor-agnostic Computational Tool to Improve Colorectal Cancer Care","SMART","Inclusion Criteria:\n\n(suspect) Lynch Syndrome carriers who:\n\n* Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor;\n* Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet;\n* Have granted informed consent to participate in this study.\n\nExclusion Criteria:\n\n(suspect) Lynch Syndrome carriers who:\n\n* Are unwilling to undergo extra blood sampling;\n* Are under the age of 18;\n* Have no newly diagnosed tumors at time of inclusion;\n* Have been treated for their tumor at time of inclusion;\n* Are not able to read or understand Dutch language or are mentally not capable.",{"count":138,"type":22},50,[140],"NA","The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages.\n\nParticipants will be asked to take an extra blood test, which will be analyzed further in the lab.",[27,36,143,144],"Colorectal Neoplasms, Hereditary Nonpolyposis","Hereditary Nonpolyposis Colon Cancer",[146,147,45,148,54,53],"Liquid Biopsy","Colorectal cancer","Prevention","2025-08-05",{"date":151,"type":61},"2025-08-11",{"date":153,"type":61},"2025-05-16",{"date":155,"type":22},"2027-02-01",{"name":157,"class":68},"Erasmus Medical Center",2,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":80,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":99},"100531517","simultaneous-vs-staged-resection-of-colorectal-cancer-with-synchronous-liver-metastases-100531517","NCT06200831","Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases","Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases - A Multicentre Randomized Controlled Trial","SYLMET","Inclusion Criteria:\n\n* Age 18-80 years old.\n* Both CRC and liver metastases in situ at time of evaluation.\n* Resectable primary tumor in the colon or upper rectum.\n* Less than 5 liver metastases, evaluated by the multidisciplinary tumor board meeting as possible to treat with surgical resection and\u002For ablation (RFA\u002FMWA).\n\nExclusion Criteria:\n\n* Unresectable primary tumor.\n* Locally advanced primary tumor (T4).\n* Primary tumor in the lower rectum with indication for abdominoperineal resection.\n* Acute or imminent bowel obstruction.\n* Perforation or major bleeding from the primary tumor.\n* Pre-treatment of the primary tumor with a colon stent.\n* Liver resection requiring resection of more than 2 adjacent segments (Couinaud).\n* Liver metastases planned treated with irreversible electroporation (IRE).\n* Non-resectable lung metastases.\n* Metastases outside of liver (besides resectable lung metastases).\n* Eastern Cooperative Oncology Group (ECOG) Performance status ≥ 3.","80 Years",{"count":169,"type":22},80,[140],"The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and\u002For ablation (RFA\u002FMWA) at time of evaluation.",[26,36,173,174],"Liver Metastasis Colon Cancer","Liver Metastases","2025-07-28",{"date":177,"type":61},"2025-07-31",{"date":179,"type":61},"2024-06-01",{"date":181,"type":22},"2031-12-31",{"name":183,"class":68},"Oslo University Hospital",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":80,"phases":193,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":99},"100532097","phase-3-localized-treatment-versus-palliative-chemotherapy-in-crc-patients-with-10-or-more-crlm-100532097","NCT06208371","Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM","The DECIDE-CRLM-10 Randomized Controlled Study: Comparison of Chemotherapy Combined With Localized Treatment for Liver Metastases Versus Palliative Chemotherapy Alone in Colorectal Patients With 10 or More Liver Metastases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed colorectal adenocarcinoma.\n* Baseline imaging (CT, MRI, or PET\u002FCT as necessary) or pathological confirmation of liver metastasis, with no extrahepatic metastasis (consideration for inclusion may be given to lesions with a diameter less than 10mm in the lungs or lymph nodes if metastasis is difficult to confirm or is suspected).\n* Disease control (PR or SD) achieved after a minimum of 8 cycles of systemic chemotherapy.\n* Evaluation by a centralized liver surgeon expert group to confirm presence of ≥10 liver metastases, which can be managed through surgery and\u002For ablation and\u002For SBRT to achieve NED. Non-resectability is defined as one or more of the following: ① Unable to undergo R0 resection; ② Predicted insufficient remaining liver volume after resection; ③ After resection, none of the three hepatic veins can be preserved, and the preservation of residual liver inflow and outflow and bile ducts cannot be guaranteed, and adjacent two liver segments cannot be preserved.\n* Curative surgery possible for the primary colorectal lesion.\n* Normal hematological, hepatic, and renal functions at baseline.\n* Child-Pugh grade A liver function.\n* ECOG performance status 0-1.\n* Tolerability to undergo further surgery and chemotherapy.\n* Life expectancy \\> 3 months.\n* Signed written informed consent.\n* Willing and able to undergo follow-up until death, study completion, or study termination.\n\nExclusion Criteria:\n\n* Definite presence of extrahepatic metastasis and\u002For primary tumor not amenable to curative surgical resection.\n* Severe arterial embolism or ascites.\n* Bleeding tendencies or coagulation disorders.\n* Hypertensive crisis or hypertensive encephalopathy.\n* Severe uncontrollable systemic complications such as infection or diabetes.\n* Clinically severe cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), uncontrolled hypertension despite appropriate medical treatment, unstable angina, congestive heart failure (NYHA 2-4), and arrhythmias requiring medication.\n* History or physical examination indicating central nervous system diseases (such as primary brain tumor, uncontrollable epilepsy, any brain metastasis, or history of stroke).\n* Diagnosis of other malignant tumors within the past 5 years (excluding basal cell carcinoma after radical surgery and\u002For cervical carcinoma in situ).\n* Pregnant or lactating women.\n* Women of childbearing potential not using or refusing to use effective non-hormonal contraceptive methods (intrauterine devices, combined barrier contraceptive methods with spermicidal gel, or sterilization) or men with reproductive potential.\n* Inability or unwillingness to comply with the study protocol.\n* Any other diseases, metastatic lesions causing functional impairment, or suspicious findings in the physical examination indicating possible contraindications for the use of investigational drugs or placing the patient at a high risk of treatment-related complications.",{"count":192,"type":22},117,[194],"PHASE3","The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question:\n\nCan localized interventions, including surgery and\u002For ablation and\u002For stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)?\n\nParticipants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and\u002For ablation and\u002For SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.",[36],[198,199,200,201,202],"Colorectal liver metastases","Overall survival","Locoregional treatment","Palliative chemotherapy","Randomized Clinical Study","2025-05-24",{"date":205,"type":61},"2025-05-30",{"date":207,"type":61},"2024-01-15",{"date":209,"type":22},"2029-06-30",{"name":211,"class":68},"Sun Yat-sen University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":77,"enrollmentInfo":219,"targetDuration":4,"studyType":80,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":99},"100565562","phase-2-evaluation-of-irinotecan-liposome-ii-combined-with-5-fu-lv-and-bevacizumab-for-mcrc-100565562","NCT06643793","Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","Evaluation of Irinotecan Liposome (II) Combined With 5-fluorouracil, Leucovorin, and Bevacizumab for Second-line\u002FThird-line Treatment of Metastatic Colorectal Cancer (mCRC): a Prospective and Exploratory Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years old and ≤ 75 years old, gender is not limited;\n2. Diagnosis of colorectal cancer by histopathology and\u002For cytology, clinical Records showing inoperable advanced metastatic colon or rectal cancer (ie, stage IV according to the UICC AJCC TNM staging system \\[8th edition 2017\\]) ;\n3. At least 1 measurable target lesion according to RECIST v1.1 criteria (ie, non-nodal lesions with a CT scan length ≥10 mm and nodal lesions with a CT scan short diameter ≥15 mm) ;\n4. Prior first- or second-line oxaliplatin-based therapy with treatment failure or intolerance\\*; Note: \\*Treatment failure or intolerance is defined as (1) disease progression during treatment or disease progression within 6 months of final treatment, both with clear evidence of imaging or clinical progression, and (2) patients who withdrew from treatment because of intolerance of an adverse event of the treatment, as per NCI-CTCAE v5.0 criteria, intolerance is defined as: a. Hematological toxicity: grade III neutropenia accompanied by fever \\>38.5°C, grade III thrombocytopenia with bleeding symptoms, and other grade IV or higher hematologic toxic reactions; b. Non-hematological toxicity: grade III or higher non-hematological toxic reactions; and c. Achievement of the above toxic reactions, which in the judgment of the investigator make continuation of the original regimen of Treatment.\n5. ECOG physical status score 0-1;\n6. Expected survival time ≥ 3 months;\n7. No major organ dysfunction, that is, the subject's organ function level and related laboratory indicators must meet the following requirements within 14 days before the first medication: (1) Blood routine (no blood transfusion, platelet transfusion, growth factors and other supportive treatments): white blood cells (WBC) ≥ 3.0 × 109\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; Platelet count (PLT) ≥ 100 × 109\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL; (2) Blood biochemistry: serum albumin (ALB) ≥ 30 g\u002FL; Alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) ≤ 2.5 times the upper normal value (ULN), and if there is liver metastasis, ALT\u002FAST ≤ 5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 60 mL\u002Fmin according to the Cockcroft-Gault formula; (3) Urine routine: urine routine indicates urine protein \\\u003C + +; If the urinary protein at baseline is ≥ + +, it is necessary to confirm that the 24-hour urinary protein quantification is ≤ 1.0 g; (4) Coagulation function (within 14 days before the first dose): prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, international normalized ratio (INR) ≤ 1.5 × ULN (no anticoagulant therapy); If the subject is treated with a stable dose of anticoagulant or vitamin K antagonist (such as warfarin, heparin or their analogues), on the premise that the international normalized ratio (INR) of prothrombin time is ≤ 1.5, it is allowed to use low-dose warfarin (1 mg orally once a day) or low-dose aspirin (not exceeding 100 mg a day) for preventive purposes; (5) Cardiac function: normal 12-lead electrocardiogram or abnormal 12-lead electrocardiogram without clinical significance judged by the investigator (i.e., QTcF \\\u003C 450 ms in men, QTcF \\\u003C 470 ms in women); Left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (i.e., LVEF ≥ 50%).\n8. Other previous antineoplastic therapy should be terminated for 4 weeks or more, and the general physical condition or associated adverse effects have recovered (toxicity ≤1 grade) or reached a stable state;\n9. Serum pregnancy test must be negative and non-lactation period in women of childbearing age within 7 days before receiving the test Women of child-bearing age or men whose partners are women of child-bearing age must agree to use medically approved contraception (e.g. , Intrauterine device, male surgical sterilization, birth control pills or condoms) for the duration of the trial;\n10. Voluntarily participate and sign an informed consent form; Ability to comply with research visit plans and other program requirements.\n\nExclusion Criteria:\n\n1. Have had a malignant tumor other than colorectal cancer within 5 years before the screening (cured skin basal cell or squamous cell carcinoma, cervical carcinoma in situ, and malignant tumors assessed by researchers as having a low risk of metastasis and death except);\n2. Tumor tissue is known to have a mismatch repair defect (DMMR) status confirmed by immunohistochemistry, or a microsatellite high instability (MSI-H) status confirmed by second-generation sequencing (NGS) polymerase chain reaction (PCR) methods, they were evaluated by the investigators as being suitable for treatment with immune checkpoint inhibitors (PD-1\u002FPD-L1 inhibitors)\n3. The second generation sequencing (NGS)\u002Fpolymerase chain reaction (PCR) method confirmed that it is a BRAF V600E mutation, which is unfavorable for patients with chemotherapy prognosis;\n4. For those who are known to have central nervous system metastases, for patients with clinically suspected central nervous system metastases, enhanced computed tomography (CT) or enhanced nuclear magnetic resonance (MRI) must be performed within 28 days before the first medication to rule out central nervous system metastases;\n5. Previous treatment with irinotecan\u002Firinotecan liposome-based chemotherapy;\n6. Use of CYP3A4, CYP2C8 and UGT1A1 strong inhibitors\u002Fstrong inducers within 14 days before starting the study. 7. Participated in other drug clinical trials within 4 weeks before the first dose;\n7. Participated in clinical trials of other drugs within 4 weeks before the first medication;\n8. Clinical records showed severe gastrointestinal dysfunction (including bleeding and obstruction; NCI-CTCAE v5.0 \\> Grade 2 inflammation; NCI-CTCAE v5.0 \\> Grade 1 diarrhea)\n9. Presence of severe comorbidities, active infections, or uncontrolled diabetes that interfere with the treatment of the trial drug: (1) uncontrolled severe medical disease that the investigators believe will affect the ability of the subject to receive treatment with the study regimen; For example, complicated with severe medical conditions, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc. (2) the occurrence of A\u002FV thrombotic event within one year before screening, such as cerebrovascular accident (including transient ischemic attack) , thrombosis disease (except venous thrombosis caused by venous catheterization during pre-chemotherapy, which is judged to be cured by researchers) , pulmonary embolism, etc. (3) imaging showed that the tumor had invaded around the important blood vessels or the patients had a high possibility of invading the important blood vessels and causing fatal massive hemorrhage (4) the subjects had active, known or suspected autoimmune diseases including systemic lupus erythematosus, Hashimoto's thyroiditis, scleroderma, Polyarteritis nodosa or autoimmune hepatitis; Participants with type 1 diabetes, hypothyroidism requiring hormone replacement only, skin conditions that do not require systemic treatment (such as leukoplakia, psoriasis, or hair loss) , or conditions that are not expected to recur without an external trigger were allowed to participate; (5) active pulmonary tuberculosis infection. Patients with active tuberculosis infection within 1 year of treatment should be excluded, even if they have been treated, and patients with a history of active tuberculosis infection more than 1 year before should be excluded, (6) previous Interstitial lung disease, or has (non-infectious) pneumonia requiring oral or intravenous steroid hormone therapy; (7) long-term treatment with systemic sex hormones (at a dose equivalent to \\> 10 mg prednisone\u002Fday) or any other form of immunosuppressive therapy is required. Subjects who used inhaled or topical corticosteroid were selected, and those who had poorly controlled cardiac clinical symptoms or conditions, such as heart failure of NYHA Class 2 or above, unstable angina, and heart failure were selected Myocardial infarction within 6 months, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, positive Hepatitis C virus antibodies to HCV or HIV; Severe infection (NCI-CTCAE v5.0 \\> 2) occurred within 4 weeks before screening, such as severe pneumonia, bacteremia, infection complications, etc. The presence of symptoms and signs of infection within 2 weeks before study initiation required intravenous antibiotic therapy (except for prophylactic antibiotic use) ; (10) subjects with grade ≥2 peripheral neuropathy according to NCI-CTCAE v5.0.\n10. Known to be allergic or intolerant to any test drug (irinotecan hydrochloride liposome injection (Ⅱ), 5-FU\u002FLV, bevacizumab) or an excipient thereof;\n11. There are known contraindications to any experimental drug (irinotecan hydrochloride liposome injection (Ⅱ), 5-FU\u002FLV, bevacizumab);\n12. Women who are pregnant, breastfeeding or have given birth but refuse to use contraception;\n13. The researcher believes that it should be excluded from this study. For example, if the researcher judges that the subject has other factors that may lead to the forced termination of this study, such as the existence of other serious diseases (including mental illness) that require combined treatment, There are serious abnormalities in laboratory tests, accompanied by family or social factors, which will affect the safety of the subject or the collection of data and samples.",{"count":220,"type":22},30,[82],"To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.",[36],"2025-01-26",{"date":226,"type":61},"2025-01-28",{"date":228,"type":61},"2024-11-04",{"date":230,"type":22},"2026-12-31",{"name":232,"class":68},"Affiliated Hospital of Nantong University",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":18,"minAge":240,"maxAge":77,"enrollmentInfo":241,"targetDuration":242,"studyType":23,"phases":4,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":99},"100571027","effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer-100571027","NCT06714903","Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer","Multi-omics Study of Intestinal Microecology in Patients with Colorectal Cancer Related to Immunotherapy","Inclusion Criteria:\n\n* Clinical and pathological diagnosis of metastatic colorectal cancer\n* 35-75 years old (both ends inclusive)\n* complete clinical information\n* signed informed consent\n\nExclusion Criteria:\n\n* combined with severe respiratory and circulatory diseases\n* combined with other malignant tumors\n* recent severe active bleeding, uncontrolled active infection or active peptic ulcer\n* moderate to severe renal insufficiency\n* other circumstances that are judged by the investigator to be unsuitable for participating in this study","35 Years",{"count":138,"type":22},"6 Months","The purpose of this observational study is to understand the effect of gut microbiota on the efficacy of immunotherapy in patients with metastatic colorectal cancer and to explore the specific mechanisms of this process. In this way, it provides new ideas for the clinical treatment of colorectal cancer.",[36],[246,247,248,249,250],"Metastatic colorectal cancer","Immunotherapy","Gut microbiota","Prognosis","Metabolism","2024-12-02",{"date":253,"type":61},"2024-12-04",{"date":255,"type":61},"2024-07-15",{"date":257,"type":22},"2025-12-31",{"name":259,"class":68},"The First Hospital of Jilin University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":80,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":275,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":4},"100521286","robotic-right-hemicolectomy-versus-laparoscopic-right-hemicolectomy-100521286","NCT06067620","Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy","Robotic Right Hemicolectomy With Intracorporeal Anastomosis Versus Laparoscopic Right Hemicolectomy With Extracorporeal Anastomosis (PRORHEM): a Randomized Controlled Trial","PRORHEM","Inclusion Criteria:\n\n* Adult patients requiring elective minimally invasive RHC for cT1-T3 Nx M0 cancer of the right colon (including cancer of the appendix, caecum, ascending colon and hepatic flexure).\n\nExclusion Criteria:\n\n* Not scheduled for minimally invasive RHC (refuses surgery and\u002For planned open approach)\n* Emergency surgery\n* Hereditary colorectal cancer\n* Inflammatory bowel disease\n* Synchronous resection of (an)other organ(s)\n* Synchronous surgical procedure (including more extended resection of the lower gastrointestinal tract)\n* cT4\n* cM+\n* History of laparotomy\n* Pregnancy\n* No anastomosis planned\n* Unable to provide informed consent\n* No informed consent",{"count":269,"type":22},70,[140],"Robotic right hemicolectomy with intra-corporeal anastomosis may have better short-term recovery outcomes and decreased incidence of incisional hernia when compared to the laparoscopic actual standard of care, for similar safety outcomes.",[27,36,273,26,28,274,29],"Colorectal Neoplasms, Benign","Colorectal Adenoma","NOT_YET_RECRUITING","2024-05-09",{"date":278,"type":61},"2024-05-10",{"date":280,"type":22},"2024-08-01",{"date":230,"type":22},{"name":283,"class":68},"Jeremy Meyer",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":23,"phases":4,"briefSummary":293,"conditions":294,"keywords":298,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":99},"100519968","factors-affecting-the-results-of-treatment-of-patients-with-colorectal-cancer-100519968","NCT06050447","Factors Affecting the Results of Treatment of Patients With Colorectal Cancer","Inclusion Criteria:\n\n* Histologically proven primary adenocarcinoma of bowel;\n* All patients who have indications for surgical treatment of colorectal cancer based on the decision of the oncological council;\n* Signed informed consent with agreement to attend all study visits;\n\nExclusion Criteria:\n\n* Unresectable tumor or contradictions to surgery;\n* Indications for chemotherapy or radiation therapy prior to surgery;\n* Patient withdrawal from the trial or loss of follow-up;\n* Emergent operation;\n* Pregnancy.",{"count":291,"type":22},1200,"3 Years","The study attempts to quantify the relative risks for mortality, anastomotic leakage and other early and late postoperative complications, recurrence rate, cancer-specific survival, recurrence-free survival after colorectal surgery for patients with colorectal cancer depending on the localization of the tumor.",[26,295,296,29,36,297],"Colon Cancer","Rectal Cancer","Rectal Adenocarcinoma",[147,118,299,300,301,302,303,304,305],"Colon cancer","Colorectal surgery","anastomotic leakage","postoperative complications","recurrence rate","cancer-specific survival","recurrence-free survival","2023-09-15",{"date":308,"type":61},"2023-09-22",{"date":310,"type":61},"2023-09-01",{"date":312,"type":22},"2026-09-01",{"name":314,"class":68},"Immanuel Kant Baltic Federal University",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":322,"targetDuration":4,"studyType":80,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":99},"100504804","postoperative-effects-of-different-enterostomy-approaches-100504804","NCT05853094","Postoperative Effects of Different Enterostomy Approaches","A Single-centre, Randomized Study to Compare the Outcomes of Protected Transverse Colostomy Versus Ileostomy After Low Anterior Resection of Low Rectal Cancer From the Perspective of Intestinal Microecology","Inclusion Criteria:\n\n1. Pathological confirmed adenocarcinoma of the rectum;\n2. Patients age between 18-80;\n3. Baseline AJCC stage I-III: cT1-4N0-2M0 (AJCC-8 version);\n4. Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 2;\n5. Patients voluntarily sign informed consent.\n\nExclusion Criteria:\n\n1. Other types of rectal cancer (adenosquamous carcinoma, squamous carcinoma, neuroendocrine tumors, clear cell carcinoma, spindle cell carcinoma, undifferentiated carcinoma);\n2. Combination of rectal cancer with multiple carcinomas;\n3. Pre-operative presence of acute and chronic infectious diseases or foci of infection;\n4. Intraoperative radical surgery was not performed for various reasons；\n5. Colostomy was not performed at the same time as the radical rectal cancer surgery;\n6. Combined with intestinal obstruction, intestinal perforation, intestinal bleeding, peritonitis, etc. requiring emergency surgery;\n7. Metastatic cancer;\n8. Serious heart, lung, liver and kidney disease, can not tolerate surgery;\n9. Active liver disease or abnormal liver function with ALT, AST and TBIL more than 2 times the upper limit of normal values;\n10. Renal impairment with Cr ≥ 2 times the upper limit of normal or BUN ≥ 2 times the upper limit of normal;\n11. Blood leukocytes below the lower limit of normal value, or platelets below the lower limit of normal value, or with other blood system diseases;\n12. Pregnancy;\n13. Mental illness or serious intellectual disability who cannot describe their feelings correctly;\n14. Severe coagulation disorder, bleeding tendency;\n15. Patients with severe uncontrolled medical disease, recent history of myocardial infarction (within 3 months), uncontrolled severe hypertension and severe diabetes mellitus;\n16. Patients need to be on antibiotics\u002Fother probiotics for a long time.",{"count":323,"type":22},300,[140],"Exploring the effect of protective ileostomy compared with transverse colostomy on the occurrence of complications, the occurrence of serious side effects of adjuvant chemotherapy and disease recurrence in patients with low rectal cancer after radical surgery from the perspective of intestinal microecology.",[26,36,327],"Intestinal Neoplasms, Malignant",[26,329],"Stoma","2023-05-17",{"date":332,"type":61},"2023-05-19",{"date":334,"type":22},"2023-06-23",{"date":336,"type":22},"2027-05",{"name":338,"class":68},"Fudan University",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":80,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":275,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":99},"100449230","chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm-100449230","NCT05129774","Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM","Concurrent Chemoradiotherapy Sequenced Radical Surgery for Para-aortic Lymph Node Metastasis of Left-sided Colon and Rectal Cancer","Inclusion Criteria:\n\n* age at enrollment is ≥ 18 and ≤ 75 years\n* ECOG PS 0-1\n* histologically confirmed left-sided colon and rectal carcinoma\n* synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below the level of renal veins and above the bifurcation of iliac artery\n* patients potential to receive surgery and achieve no evidence of disease (NED)\n* able to tolerate surgery\n* providing written informed consent\n\nExclusion Criteria:\n\n* local invasion or distant metastasis other than para-aoritc lymph nodes\n* history of other malignant tumor\n* coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection)\n* emergency surgery","70 Years",{"count":348,"type":22},40,[140],"In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%. Currently, there has been no standard treatment strategy for this situation. The present trial is designed to evaluate the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal cancer with synchronous para-aortic lymph node metastasis",[36,352,353],"Lymph Node Excision","Chemoradiotherapy","2021-11-18",{"date":356,"type":61},"2021-11-22",{"date":358,"type":22},"2022-01-01",{"date":360,"type":22},"2027-01-01",{"name":362,"class":68},"Qilu Hospital of Shandong University"]